Dan Salvo, Author at Forge Biologics

United Leukodystrophy Foundation

Posted on January 27, 2021 (April 29, 2021)

We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing […]

VIDEO: Manufacturing Capabilities

Posted on January 25, 2021 (April 29, 2021)

We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements. […]

“Building Better” Blog: Forge Biologics Spotlight

Posted on January 22, 2021 (April 29, 2021)

We are thrilled to have a spotlight in National Venture Capital Association‘s (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive […]

RESKUE Trial for Patients with Krabbe Disease

Posted on January 21, 2021 (April 29, 2021)

With new beginnings comes new hope. As we enter 2021, screening will begin for the our Phase 1/2 RESKUE trial […]

Announcing: Blaze Vector™ Production

Posted on January 12, 2021 (April 29, 2021)

As we begin 2021, we’d like to introduce you to our new Blaze Vector™ AAV production line. Utilizing our proprietary […]

Our Gene Therapy Players: The Starting Lineup

Posted on December 23, 2020 (April 29, 2021)

In the spirit of football season, we’re introducing our very own roster of seasoned #genetherapy players. Our leadership team has […]

Happy Holidays: Hope is Alive!

Posted on December 23, 2020 (January 27, 2021)

From all of us at Forge Biologics, we wish you a safe and happy holiday season!#hopeisalive #happyholidays #raredisease #genetherapy #aav #lifesciences #innovation #biotechnology #GMP […]

Here to Stay

Posted on December 11, 2020 (January 3, 2021)

Forge Biologics is a #genetherapy manufacturing and development company helping clients achieve their cGMP program goals. Forge enables AAV vector production at […]

You in?

Posted on September 25, 2020 (January 3, 2021)

Your next career is here. https://www.forgebiologics.com/careers […]